Hypha Labs, Inc. Overview
Pro stress-test →Hypha Labs develops and commercializes the Hypha Micropearl bioreactor, a home appliance designed to accelerate production of beneficial mushrooms for human consumption. The company was approved to trade under ticker FUNI on August 13, 2024, following a name change from Digipath.
Strategic Profile
Pro stress-test →Hypha Labs has developed the first in-home mushroom accelerator to allow production of high-quality mushroom ingredients in an eight-day cycle. The company is currently conducting a Regulation A+ public offering to support expansion from consumer devices to large-scale ingredient production.
Competitive Landscape
Pro stress-test →Hypha Labs operates in the home mushroom cultivation niche with limited direct competitors. The broader functional mushroom supplement market includes traditional dried mushroom suppliers and ingredient manufacturers, but no established home appliance-based mushroom production competitors are well-documented. The company's closest conceptual comparison is consumer biotech hardware (like kombucha makers) rather than traditional supplement brands.
Industry Context
Hypha Labs, Inc. operates in Consumer biotechnology hardware and home food cultivation devices.
Key facts
Founded: 2010 · Headquarters: Las Vegas, Nevada · Employees: Unknown · Revenue: Estimated $0 (no commercial revenue reported as of July 2026) · Market cap: $5.9M